Nessa Carey

Last updated

Nessa Carey
Nessa Carey at Eastbourne SitP feb 2015.jpg
Nessa Carey at Eastbourne Sceptics in the Pub in February 2015 after her Epigenetics talk. [1]
NationalityBritish
Alma mater University of Edinburgh
Known forThe Epigenetics Revolution; Junk DNA: A Journey Through the Dark Matter of the Genome
Scientific career
Fields Epigenetics, Technology Transfer
Institutions Imperial College London
Thesis Studies on the extracellular envelope glycoprotein of maedi-visna virus. [2]
Website http://www.nessacarey.co.uk/

Nessa Carey is a British biologist working in the field of molecular biology and biotechnology. She is International Director of the technology transfer organization PraxisUnico and a visiting professor at Imperial College London.

Contents

With expertise in the field of epigenetics and in technology transfer, she promotes the movement of scientists between academia and industry, lecturing often to school students and early career scientists. Carey writes books and articles for a scientifically interested general audience. She is the author of The Epigenetics Revolution [3] and Junk DNA: A Journey Through the Dark Matter of the Genome [4] which explore advances in the field of epigenetics and their implications for medicine. She edited Epigenetics for Drug Discovery [5] for the Royal Society of Chemistry's Drug Discovery Series. [6]

Education and career

Carey attended state schools. [7] She first attended the University of Edinburgh to study veterinary medicine. Having limited aptitude for the course and reacting badly to animal fur she left veterinary studies. [8]

"This didn't last because I was allergic to fur, unable to think in 3D (not good for anatomy), quite bored and really rubbish at the course."

— Nessa Carey [8]

She then worked for five years in the Metropolitan Police forensic science laboratory as a forensic scientist. [8] After studying for her degree in immunology part-time, Carey decided to continue academic research and returned to the University of Edinburgh to pursue doctoral studies. Carey was awarded her Doctorate (PhD) by research thesis on the virology of the maedi-visna virus which affects sheep, in 1993. [8] [2]

Her post-doctoral research was in the field of human genetics at the Department of Anatomy, Charing Cross and Westminster Medical School after which she became a lecturer, and then senior lecturer, in molecular biology at Imperial College London, School of Medicine. [9] [10] In 2001 she left academia to work in industry although since 2013 she has been a Visiting Professor in the Department of Surgery and Cancer at Imperial College London [11] in conjunction with her professional career.

Carey was director of molecular biology at Vernalis from 2001 until 2004. [12] She then held positions as Head of Biology at TopoTarget from 2004 to 2006 [10] and Scientific Director at CellCentric from 2006 to May 2011. [12] From May 2011 until July 2014 she was Senior Director in External Research and Development Innovation at Pfizer [13] [10] where she focused on identifying new collaborative opportunities in the field of epigenetics. [14] She has been International Director at PraxisUnico since July 2014. [10]

Carey was a Member of the Bioscience for Industry Strategy Advisory Panel of the Biotechnology and Biological Sciences Research Council (BBSRC) [15] from 2011 to 2015; a Member of the Molecular and Cellular Medicine Board of the Medical Research Council (MRC) from 2011 to 2015 [13] and a Scientific Steering Committee member for the MRC Epigenetics workshop in 2015. [16]

Carey's expertise has expanded from biology to include communication and training. She is a Registered Technology Transfer Professional (RTTP). Her achievements include delivering training at Imperial College School of Medicine and the Royal College of Surgeons (UK and Ireland). [10] She is active in promoting movement of scientists between academia and industry and often discusses choices with early career scientists. [17] [18] [19] [20]

When opportunity comes knocking, it's best not to be in the shower ... I think of myself of someone who has had a lot of careers in science, rather than one scientific career.

— Nessa Carey [21]

Publications

Carey's books and lectures explain developments in epigenetics to a scientifically interested general audience. [22] [23] [24] Carey has published over 30 peer-reviewed papers on epigenetics and other aspects of biology. She also writes in the popular press examining popular culture and media from a scientific viewpoint. [25] [26] [27]

The Epigenetics Revolution: How Modern Biology Is Rewriting Our Understanding of Genetics, Disease, and Inheritance

Carey suggests that Audrey Hepburn's slight figure may be the product of epigenetic changes from wartime deprivation. Audrey Hepburn screentest in Roman Holiday trailer 2.jpg
Carey suggests that Audrey Hepburn's slight figure may be the product of epigenetic changes from wartime deprivation.

Her first book, The Epigenetics Revolution, [3] describes how epigenetic modifications allow the same DNA to express different characteristics; she likens DNA to a script for a play rather than a template. The same script can produce different productions of the play. [28]

She used the example of Audrey Hepburn's slight figure to explain the possible impacts of epigenetics. [28] Hepburn's figure was a result of lifelong illnesses brought on by her deprivation during the Dutch famine of 1944–45 during World War II. Carey's book says we aren't simply born with pre-set genes and the way genes function can be altered 'epigenetically' by our environments or diets. These changes can subsequently impact future generations. [28] The book discusses controversies which are a part of this rapidly developing field and explores explanations other than epigenetics for some findings. [29]

Peter Forbes of The Guardian wrote that while the book does not simplify scientific terminology for the general reader, it "is the first to set out the epigenetics stall for the general reader, and anyone seriously interested in who we are and how we function should read this book". [30] Other reviewers also found the book "a bit jargon heavy", [31] while some felt this was "not so much her fault as the nature of biology". [32] Alexander Badyaev writes that "you cannot help but admire the author who is so fluent in such a great diversity of topics". [33]

Junk DNA: A Journey Through the Dark Matter of the Genome

Carey's second book, Junk DNA: A Journey Through the Dark Matter of the Genome, [4] examines developments in the study of junk DNA, or noncoding DNA. DNA that doesn't code for proteins has been dismissed as nonfunctional until recently. She explains the "most fundamental reason for the shift in emphasis is the sheer volume of junk DNA that our cells contain. One of the biggest shocks when the human genome sequence was completed in 2001 was the discovery that over 98 per cent of the DNA in a human is junk. It doesn't code for any proteins." [4] : 2  Carey describes how this Junk DNA

maintains the integrity of our chromosomes; regulates the ways the protein-coding genes are expressed; influences how we age and generally introduces incredible degrees of subtlety and flexibility into how we use the relatively small numbers of genes that code for proteins ... [and] contributes to all sorts of situations, from the correct control of gene expression in female cells to the regulation of pathways that drive cancer. From Ernest Hemingway's mutant cat to exoneration of the innocent through DNA fingerprinting, junk DNA impacts on an astonishing range of biological phenomena. [34]

The book uses analogy to explain molecular phenomena. Although there is some criticism that the book's coverage is "too comprehensive for the general reader" and "lacks an overarching, compelling narrative to carry readers through", reviewer Linda Geddes called it "a cutting-edge, exhaustive guide to the rapidly changing, ever-more mysterious genome." [35] It is recommended for "any nonspecialist who would like a captivating, thorough, and up-to-date introduction...[to] the bigger picture of our wonderful and messy genome." [36]

Carey describes the controversy and politics around this field: "At one extreme we have scientists claiming experimental proof is lacking to support sometimes sweeping claims. At the other are those who feel there is a whole generation of scientists (if not more) trapped in an outdated model and unable to see or understand the new order." [4] : 6  While some reviewers have criticised her style, a few also attack her science. [37]

Epigenetics for Drug Discovery

Edited by Carey, Epigenetics for Drug Discovery, [5] is "written by the leading researchers in this field. It is intended as a guide for medicinal chemists or scientists in other fields wishing to know more." [38] This book examines the field of epigenetics, its possible applications to medicine and the challenges in using the research safely and efficaciously. [39] It includes for example: a chapter by Karl P. Nightingale which defines epigenetics and explains why it matters; [40] a chapter by Tom D. Heightman and Michael McCullar which focuses "on the biochemical mechanisms controlling DNA methylation, consequences of aberrant DNA methylation in complex chronic diseases, existing modulators of DNA methylation used in the clinic, and opportunities for new drugs targeting this central epigenetic mechanism" [41] and a chapter titled "Progress in Targeting Epigenetic Readers" by Chun-Wa Chung. [42]

This book is part of the Royal Society of Chemistry's Drug Discovery Series [6] which includes over fifty volumes published since 2010 in the fields of drug discovery and medicinal chemistry. "Providing comprehensive coverage of this important and far-reaching area, the books encourage learning in a range of different topics and provide valuable reference for scientists working outside their own areas of expertise." [6]

Hacking the Code of Life: How Gene Editing Will Rewrite Our Futures (2019)

This book discusses a new technique for genetic modification called CRISPR. This system allows the scientists to precisely and easily manipulate the genes of any living organism in a short period of time. The book further discusses the ethical limitations in the implementation of these methods on human beings. Carey gives a snapshot of the technology that is possibly going to change the future of gene editing. [43]

Related Research Articles

<span class="mw-page-title-main">Human genome</span> Complete set of nucleic acid sequences for humans

The human genome is a complete set of nucleic acid sequences for humans, encoded as DNA within the 23 chromosome pairs in cell nuclei and in a small DNA molecule found within individual mitochondria. These are usually treated separately as the nuclear genome and the mitochondrial genome. Human genomes include both protein-coding DNA sequences and various types of DNA that does not encode proteins. The latter is a diverse category that includes DNA coding for non-translated RNA, such as that for ribosomal RNA, transfer RNA, ribozymes, small nuclear RNAs, and several types of regulatory RNAs. It also includes promoters and their associated gene-regulatory elements, DNA playing structural and replicatory roles, such as scaffolding regions, telomeres, centromeres, and origins of replication, plus large numbers of transposable elements, inserted viral DNA, non-functional pseudogenes and simple, highly repetitive sequences. Introns make up a large percentage of non-coding DNA. Some of this non-coding DNA is non-functional junk DNA, such as pseudogenes, but there is no firm consensus on the total amount of junk DNA.

<span class="mw-page-title-main">Epigenetics</span> Study of DNA modifications that do not change its sequence

In biology, epigenetics is the study of heritable traits, or a stable change of cell function, that happen without changes to the DNA sequence. The Greek prefix epi- in epigenetics implies features that are "on top of" or "in addition to" the traditional genetic mechanism of inheritance. Epigenetics usually involves a change that is not erased by cell division, and affects the regulation of gene expression. Such effects on cellular and physiological phenotypic traits may result from environmental factors, or be part of normal development. They can lead to cancer.

<span class="mw-page-title-main">Leroy Hood</span> American biologist (born 1938)

Leroy "Lee" Edward Hood is an American biologist who has served on the faculties at the California Institute of Technology (Caltech) and the University of Washington. Hood has developed ground-breaking scientific instruments which made possible major advances in the biological sciences and the medical sciences. These include the first gas phase protein sequencer (1982), for determining the sequence of amino acids in a given protein; a DNA synthesizer (1983), to synthesize short sections of DNA; a peptide synthesizer (1984), to combine amino acids into longer peptides and short proteins; the first automated DNA sequencer (1986), to identify the order of nucleotides in DNA; ink-jet oligonucleotide technology for synthesizing DNA and nanostring technology for analyzing single molecules of DNA and RNA.

<span class="mw-page-title-main">Molecular genetics</span> Scientific study of genes at the molecular level

Molecular genetics is a branch of biology that addresses how differences in the structures or expression of DNA molecules manifests as variation among organisms. Molecular genetics often applies an "investigative approach" to determine the structure and/or function of genes in an organism's genome using genetic screens. 

<span class="mw-page-title-main">Medical Research Council (United Kingdom)</span> National medical research agency

The Medical Research Council (MRC) is responsible for co-coordinating and funding medical research in the United Kingdom. It is part of United Kingdom Research and Innovation (UKRI), which came into operation 1 April 2018, and brings together the UK's seven research councils, Innovate UK and Research England. UK Research and Innovation is answerable to, although politically independent from, the Department for Business, Energy and Industrial Strategy.

<span class="mw-page-title-main">Molecular Structure of Nucleic Acids: A Structure for Deoxyribose Nucleic Acid</span> 1953 scientific paper on the helical structure of DNA by James Watson and Francis Crick

"Molecular Structure of Nucleic Acids: A Structure for Deoxyribose Nucleic Acid" was the first article published to describe the discovery of the double helix structure of DNA, using X-ray diffraction and the mathematics of a helix transform. It was published by Francis Crick and James D. Watson in the scientific journal Nature on pages 737–738 of its 171st volume.

<span class="mw-page-title-main">London Research Institute</span> Biological research facility

The Cancer Research UK London Research Institute (LRI) was a biological research facility which conducted research into the basic biology of cancer.

<span class="mw-page-title-main">Joan A. Steitz</span> American biochemist

Joan Elaine Argetsinger Steitz is Sterling Professor of Molecular Biophysics and Biochemistry at Yale University and Investigator at the Howard Hughes Medical Institute. She is known for her discoveries involving RNA, including ground-breaking insights into how ribosomes interact with messenger RNA by complementary base pairing and that introns are spliced by small nuclear ribonucleic proteins (snRNPs), which occur in eukaryotes. In September 2018, Steitz won the Lasker-Koshland Award for Special Achievement in Medical Science. The Lasker award is often referred to as the 'American Nobel' because 87 of the former recipients have gone on to win Nobel prizes.

<span class="mw-page-title-main">Maxine Singer</span> American biologist

Maxine Frank Singer is an American molecular biologist and science administrator. She is known for her contributions to solving the genetic code, her role in the ethical and regulatory debates on recombinant DNA techniques, and her leadership of Carnegie Institution of Washington. In 2002, Discover magazine recognized her as one of the 50 most important women in science.

<span class="mw-page-title-main">Adrian Bird</span> British geneticist and professor

Sir Adrian Peter Bird, is a British geneticist and Buchanan Professor of Genetics at the University of Edinburgh. Bird has spent much of his academic career in Edinburgh, from receiving his PhD in 1970 to working at the MRC Mammalian Genome Unit and later serving as director of the Wellcome Trust Centre for Cell Biology. His research focuses on understanding DNA methylation and CpG islands, and their role in diseases such as Rett syndrome.

<span class="mw-page-title-main">Jennifer Doudna</span> American biochemist and Nobel laureate (born 1964)

Jennifer Anne Doudna is an American biochemist who has done pioneering work in CRISPR gene editing, and made other fundamental contributions in biochemistry and genetics. Doudna was one of the first women to share a Nobel in the sciences. She received the 2020 Nobel Prize in Chemistry, with Emmanuelle Charpentier, "for the development of a method for genome editing." She is the Li Ka Shing Chancellor's Chair Professor in the department of chemistry and the department of molecular and cell biology at the University of California, Berkeley. She has been an investigator with the Howard Hughes Medical Institute since 1997.

Ashok Venkitaraman is a British cancer researcher of Indian origin. He is the Director of the Cancer Science Institute of Singapore, a Distinguished Professor of Medicine at the National University of Singapore, and Program Director at A*STAR, Singapore. From 1998 to 2020, he was the inaugural holder of the Ursula Zoellner Professorship of Cancer Research at the University of Cambridge, a Professorial Fellow at Pembroke College, Cambridge, and from 2006 to 2019, was the Director of the Medical Research Council Cancer Unit.

<span class="mw-page-title-main">Amanda Fisher</span> British cell biologist

Dame Amanda Gay Fisher is a British cell biologist and Director of the Medical Research Council (MRC) London Institute of Medical Sciences at the Hammersmith Hospital campus of Imperial College London, where she is also a Professor leading the Institute of Clinical Sciences. She has made contributions to multiple areas of cell biology, including determining the function of several genes in HIV and describing the importance of a gene's location within the cell nucleus.

Katharine Luisa Arney is a British science communicator, broadcaster, author, and the founder and creative director of communications consultancy First Create the Media. She was a regular co-host of The Naked Scientists, a BBC Radio programme and podcast, and also hosted the BBC Radio 5 Live Science Show and the BBC Radio 4 series Did the Victorians Ruin the World She has written numerous articles and columns for Science, The Guardian, New Scientist the BBC and others.

Shantanu Chowdhury is an Indian structural biologist and a professor at Institute of Genomics and Integrative Biology of the Council of Scientific and Industrial Research. He is known for developing a mechanism for gene regulation mediated by DNA Secondary-Structure in diverse cellular contexts. An elected fellow of the National Academy of Sciences, India, he is a recipient of the National Bioscience Award for Career Development of the Department of Biotechnology in 2010. The Council of Scientific and Industrial Research, the apex agency of the Government of India for scientific research, awarded him the Shanti Swarup Bhatnagar Prize for Science and Technology, one of the highest Indian science awards, in 2012, for his contributions to biological sciences.

<i>The Compatibility Gene</i> 2013 book by Daniel M. Davis

The Compatibility Gene is a 2013 book about the discovery of the mechanism of compatibility in the human immune system by the English professor of immunology, Daniel M. Davis. It describes the history of immunology with the discovery of the principle of graft rejection by Peter Medawar in the 1950s, and the way the body distinguishes self from not-self via natural killer cells. The compatibility mechanism contributes also to the success of pregnancy by helping the placenta to form, and may play a role in mate selection.

<span class="mw-page-title-main">CRISPR gene editing</span> Gene editing method

CRISPR gene editing standing for "Clustered Regularly Interspaced Short Palindromic Repeats" is a genetic engineering technique in molecular biology by which the genomes of living organisms may be modified. It is based on a simplified version of the bacterial CRISPR-Cas9 antiviral defense system. By delivering the Cas9 nuclease complexed with a synthetic guide RNA (gRNA) into a cell, the cell's genome can be cut at a desired location, allowing existing genes to be removed and/or new ones added in vivo.

Ana Pombo is an appointed Professor (W3) of Biology at Humboldt University and senior group leader at the Berlin Institute for Medical Systems Biology (BIMSB) at the Max Delbrück Center for Molecular Medicine (MDC) in Berlin-Buch with the focus on "Epigenetic Regulation and Chromatin Architecture". Since May 2018, Pombo is an elected member of the European Molecular Biology Organization (EMBO).

<span class="mw-page-title-main">M. Madan Babu</span> Indian-American computational biologist

M. Madan Babu is an Indian-American computational biologist and bioinformatician. He is the endowed chair in biological data science and director of the center of excellence for data-driven discovery at St. Jude Children's Research Hospital. Previously, he served as a programme leader at the MRC Laboratory of Molecular Biology (LMB).

Target 2035 is a global effort or movement to discover open science, pharmacological modulator(s) for every protein in the human proteome by the year 2035. The effort is led by the Structural Genomics Consortium with the intention that this movement evolves organically. Target 2035 has been borne out of the success that chemical probes have had in elevating or de-prioritizing the therapeutic potential of protein targets. The availability of open access pharmacological tools is a largely unmet aspect of drug discovery especially for the dark proteome.

References

  1. ↑ "The Epigenetics Revolution – Wednesday, February 25 at 8:00PM". eastbourne.skepticsinthepub.org. Retrieved 22 January 2017.
  2. 1 2 Carey, N (1993). Studies on the extracellular envelope glycoprotein of maedi-visna virus. British Library EThOS – Thesis details (Ph.D). Archived from the original on 5 February 2017. Retrieved 30 April 2015.
  3. 1 2 Carey, Nessa (22 January 2017). The Epigenetics Revolution: How Modern Biology Is Rewriting Our Understanding of Genetics, Disease, and Inheritance. Columbia University Press. ISBN   9780231530712.
  4. 1 2 3 4 Carey, Nessa (22 January 2017). Junk DNA: A Journey Through the Dark Matter of the Genome. Columbia University Press. ISBN   9780231539418.
  5. 1 2 Carey, Nessa, ed. (20 November 2015). Epigenetics for Drug Discovery. Royal Society of Chemistry (RSC) Publishing. doi:10.1039/9781782628484. ISBN   9781849738828.
  6. 1 2 3 Brenneman, Jehrod; Iyer, Malliga R, eds. (2019). RSC Drug Discovery. Royal Society of Chemistry. doi:10.1039/2041-3211. ISBN   978-1-78801-433-5 . Retrieved 28 January 2017.{{cite book}}: |website= ignored (help)
  7. ↑ "Professor Nessa Carey – Speakers for Schools". www.speakers4schools.org. Retrieved 13 February 2017.
  8. 1 2 3 4 "About Me" . Retrieved 1 April 2015.
  9. ↑ "Nessa Carey eBooks". eBookMall. Retrieved 1 April 2015.
  10. 1 2 3 4 5 "International Trainers | Dr Nessa Carey". Praxis Unico. Retrieved 22 January 2017.[ permanent dead link ]
  11. ↑ "Minutes of the Council of the Imperial College of Science, Technology and Medicine" (PDF). Imperial College Website. p. 251. Retrieved 2 May 2015. Dr Nessa CAREY has been offered an association with the College as Visiting Professor, in the Department of Surgery and Cancer, Faculty of Medicine, with effect from 1 February 2013.
  12. 1 2 "People". Nature Biotechnology. 24 (8): 1038. 1 August 2006. doi: 10.1038/nbt0806-1038 . S2CID   219544127.
  13. 1 2 "PhD Nessa Carey – AcademiaNet". www.academia-net.org. Retrieved 22 January 2017.
  14. ↑ "2014: Nessa Carey, Pfizer | MRC Integrative Epidemiology Unit". University of Bristol. Retrieved 22 January 2017.
  15. ↑ "Bioscience for Industry Strategy Advisory Panel – BBSRC". Biotechnology and Biological Sciences Research Council. Retrieved 22 January 2017.
  16. ↑ Medical Research Council (2015). Meeting Report : MRC Epigenetics workshop. The Oakley Court. Windsor. Berkshire. UK.{{cite book}}: CS1 maint: location missing publisher (link)
  17. ↑ "From academia to industry with Nessa Carey : Naturejobs Blog". blogs.nature.com. Retrieved 23 January 2017.
  18. ↑ "Imperial MRC Colloquium | Imperial College London". www.imperial.ac.uk. Retrieved 27 January 2017.
  19. ↑ "Medicinal Chemistry Residential School". www.rsc.org. Retrieved 27 January 2017.
  20. ↑ Medicine at Imperial College London (27 August 2014). "Professor Nessa Carey: 'Science for Life – More career opportunities than you think?'". YouTube . Retrieved 27 January 2017.
  21. ↑ "International Director, Visiting Professor and author: Nessa Carey". Medical Research Council. 16 March 2015. Retrieved 23 January 2017.
  22. ↑ Carey, Nessa (2015). "An introduction to epigenetics". Ri Channel. Retrieved 27 January 2017.
  23. ↑ Carey, Nessa (19 February 2015). "The epigenomics roadmap: more exciting than the Genome Project?". BBC World Service Radio. Retrieved 27 January 2017.
  24. ↑ Carey, Nessa (25 February 2015). "The Epigenetics Revolution. Part of the Brighton Science Festival". Eastbourne Sceptics in the Pub. Retrieved 27 January 2017.
  25. ↑ Carey, Nessa (13 October 2015). "The Epigenetics of Sexuality – Wrong on So Many Levels". The Huffington Post. Retrieved 13 February 2017.
  26. ↑ Carey, Nessa (26 February 2015). "Extinctions and the Death of the Human Imagination". The Huffington Post. Retrieved 13 February 2017.
  27. ↑ Carey, Nessa (30 September 2014). "Why Scientists Need to Stop Being People Pleasers". The Huffington Post. Retrieved 13 February 2017.
  28. 1 2 3 "Beyond DNA: Epigenetics". Natural History Magazine. Retrieved 26 January 2017.
  29. ↑ The Epigenetics Revolution by Nessa Carey. 2012.{{cite book}}: |work= ignored (help)
  30. ↑ Forbes, Peter (19 August 2011). "The Epigenetics Revolution by Nessa Carey – review". The Guardian. Retrieved 27 January 2017.
  31. ↑ Carey, Nessa (12 September 2011). "Gene action: a review of The Epigenetics Revolution". Sakaal Times. Retrieved 27 January 2017.
  32. ↑ "Review – The Epigenetics Revolution". Popular Science. Retrieved 27 January 2017.
  33. ↑ Badyaev, Alexander V. (1 March 2013). "Defining Epigenetics in Deterministic Terms". BioScience. 63 (3): 224–227. doi: 10.1525/bio.2013.63.3.11 .
  34. ↑ Carey, Nessa. "Junk DNA – The Basics". www.nessacarey.co.uk. Retrieved 27 January 2017.
  35. ↑ Geddes, Linda (4 February 2015). "An encyclopaedic guide to the dark genome". New Scientist. Retrieved 26 January 2017.
  36. ↑ Lents, Nathan H. (3 August 2015). "Junk DNA: A Journey Through the Dark Matter of the Genome". The Human Evolution Blog. Retrieved 27 January 2017.
  37. ↑ Moran, Laurence A. (10 February 2015). "Sandwalk: Nessa Carey and New Scientist don't understand the junk DNA debate". Sandwalk. Retrieved 28 January 2017.
  38. ↑ Carey, Nessa (2016). "Epigenetics – from under the radar to over the top?" (PDF). RSC News. March 2016: 14.
  39. ↑ Carey, Nessa, ed. (2016). Epigenetics for Drug Discovery. The Royal Society of Chemistry. doi:10.1039/9781782628484. ISBN   9781849738828.
  40. ↑ Nightingale, Karl P. (20 November 2015). "CHAPTER 1. Epigenetics – What it is and Why it Matters". In Carey, Nessa (ed.). Epigenetics for Drug Discovery. pp. 1–19. doi:10.1039/9781782628484-00001. ISBN   978-1-84973-882-8.
  41. ↑ Heightman, Tom D.; McCullar, Michael (20 November 2015). "CHAPTER 4. Targeting DNA Methylation". In Carey, Nessa (ed.). Epigenetics for Drug Discovery. pp. 68–95. doi:10.1039/9781782628484-00068. ISBN   978-1-84973-882-8.
  42. ↑ Chung, Chun-Wa (20 November 2015). Carey, Nessa (ed.). Chapter 8: Progress in Targeting Epigenetic Readers. Royal Society of Chemistry. pp. 192–220. ISBN   9781849738828.{{cite book}}: |work= ignored (help)
  43. ↑ Carey, Nessa (7 March 2019). Hacking the Code of Life: How Gene Editing Will Rewrite Our Futures. Icon Books, Limited. ISBN   9781785784972.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.